Video Insights
Advertisement
Ryan Jacobs, MD discusses 2025 CLL treatment advances, including BTK/BCL-2 combos, resistance, and time-defined strategies.
Charles Gaulin, MBBS, discussed the future of lymphoma treatment, including the development of novel cellular therapies.
Naval Daver, MD, discusses the latest advancements in the treatment of myelodysplastic syndromes
Charles Gaulin, MBBS, discussed the safety and efficacy of CD19 CAR-T cell therapy for transformed indolent lymphoma.
Kelly Chien, MD, discusses how disparities in access to care, resources, and molecular testing impact outcomes in AML.
Anderw Brunner, MD addresses current gaps in MDS research and clinical practice and more.
Nirav Shah, MD, MSHP, tells BCT about his team's phase I/II clinical trial findings.
Sairah Ahmed, MD, tells about current management challenges and promising developments in treatment options.
Seta Degann, MD, resident physician at George Washington University, described the challenges of diagnosing younger patients.
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Stephen M. Ansell, MD, PhD, explains the importance of making an accurate diagnosis of Hodgkin lymphoma.
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
CML clinical expert Nikolai Podoltsev, MD, PhD, especially addresses the capabilities of tyrosine kinase inhibitors.
Mark Sorial, PharmD, BCOP, shared the latest research from the Salvia Jain Lab's PETAL Consortium.
Some major themes for practice include identifying patients at risk for early progression and emphasis on quality of life.
Dr. Shah discusses the significance and limitations of two studies on dietary factors and risk of myeloma and MGUS.
A plant-based diet is significantly associated with a reduced risk of multiple myeloma.
A US population-based study investigated the associations between MGUS and various dietary patterns.
The expert panel describes outstanding clinical research needs in DLBCL and what research underway they find exciting.
Expert clinicians describe which factors they consider when selecting between these two interventions for DLBCL management.
An expert panel discusses utilizing molecular strategies to determine treatment decisions for DLBCL.
In this DLBCL roundtable, experts share which novel agents or combinations they are most interested in.
Ruemu Birhiray, MD, leads an expert roundtable on the current treatment pathway in DLBCL.
The expert panel assesses the current and expected utility for clinicians of MRD in DLBCL management decisions.
With insights into next-generation therapies, this discussion explores what’s ahead in the follicular lymphoma landscape.
Ruemu Birhiray, MD of Hematology Oncology of Indiana leads the continuation of a roundtable discussion on FL treatment.
Three experts analyze data on combination therapy for FL, including efficacy, safety, and strategy adoption.
Dr. Nowakowski encourages physicians to refer patients to clinical trials exploring a novel mechanism for CNS lymphoma.
Resistance remains a challenge in central nervous system lymphoma, creating a need for novel therapeutic combinations.
The TakeAim study explores dual inhibition with BTK and IRAK4 inhibitors.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.